Bausch Health vs JPMorgan Chase: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Bausch Health and JPMorgan Chase side by side

1. 1799JPMorgan Chase

   Manhattan Company Chartered

   Aaron Burr and Alexander Hamilton led the effort to obtain a New York charter for the Manhattan Company.

2. 1871JPMorgan Chase

   Drexel, Morgan & Co. Formed

   J. Pierpont Morgan and Anthony Drexel formed Drexel, Morgan & Co. in New York. The partnership developed into J.P. Morgan & Co., creating the Morgan banking lineage that would remain separate from Chase until the companies combined in 2000.

3. 1907JPMorgan Chase

   Panic of 1907

   During the Panic of 1907, J. Pierpont Morgan organized bankers and other private participants to support strained financial institutions. The episode became a defining part of the Morgan firm's history in an era before the Federal Reserve existed.

4. 1955JPMorgan Chase

   Chase Manhattan Created

   The Bank of the Manhattan Company merged with Chase National Bank to form Chase Manhattan Bank. This combination joined the firm's oldest 1799 predecessor with the Chase name and created the institution that later merged with J.P. Morgan.

5. 1959Bausch Health

   Milan Panic founds ICN Pharmaceuticals

   Milan Panic, a Yugoslav immigrant to California, founded ICN Pharmaceuticals in 1959 and ran it for four decades. ICN is the predecessor of Valeant Pharmaceuticals and of today's Bausch Health.

6. 1994Bausch Health

   Biovail Corporation International formed in Canada

   On March 29, 1994 Eugene Melnyk consolidated his Canadian drug-delivery business by amalgamating Trimel Corporation with its subsidiary to create Biovail Corporation International, the legal entity that files today as Bausch Health Companies Inc.

7. 2000JPMorgan Chase

   Chase and J.P. Morgan Merge

   Chase Manhattan and J.P. Morgan & Co. completed their merger, combining commercial and consumer banking with investment banking and institutional services. JPMorgan Chase identifies this transaction as the formation of the modern company.

8. 2003Bausch Health

   ICN renames itself Valeant Pharmaceuticals

   ICN Pharmaceuticals, then based in Costa Mesa, California, took the Valeant Pharmaceuticals name in November 2003 to distance itself from the governance fights of the Panic era.

9. 2004JPMorgan Chase

   Bank One Merger

   JPMorgan Chase completed its $58.546 billion stock-for-stock merger with Bank One on July 1.

10. 2006JPMorgan Chase

    Jamie Dimon Becomes CEO

    Jamie Dimon succeeded William B. Harrison Jr. as chief executive on January 1. Dimon had joined JPMorgan Chase as president and chief operating officer when the Bank One merger closed and became chairman one year after becoming CEO.

11. 2008Bausch Health

    J. Michael Pearson becomes chief executive

    Valeant appointed former McKinsey director J. Michael Pearson as chief executive effective February 1, 2008, succeeding Timothy C. Tyson. Pearson replaced internal research spending with debt-funded acquisitions of marketed drugs.

12. 2008JPMorgan Chase

    Bear Stearns Acquired

    JPMorgan Chase completed its acquisition of Bear Stearns during the financial crisis.

13. 2008JPMorgan Chase

    Washington Mutual Operations Acquired

    After Washington Mutual Bank entered FDIC receivership, JPMorgan Chase paid $1.9 billion to acquire its banking operations, including assets, deposits, and qualified financial contracts under the transaction terms.

14. 2010Bausch Health

    Biovail and Valeant complete their merger

    The merger of Biovail Corporation and Valeant Pharmaceuticals International closed on September 28, 2010. The combined company kept the Valeant name and Pearson as chief executive but was incorporated in Canada.

15. 2011Bausch Health

    Ortho Dermatologics bought from Johnson and Johnson

    Valeant agreed to acquire the U.S. Ortho Dermatologics assets from Janssen Pharmaceuticals, a Johnson and Johnson company, for about $345M in cash, building the dermatology franchise.

16. 2013Bausch Health

    Bausch + Lomb acquired for $8.7 billion

    Valeant agreed in May 2013 to buy eye-health company Bausch + Lomb from Warburg Pincus for $8.7B in cash, adding contact lenses, lens care, ophthalmic drugs and surgical devices.

17. 2015Bausch Health

    Salix acquisition closes at about $11.1 billion

    Valeant completed its tender offer for Salix Pharmaceuticals on April 1, 2015 at $173 per share, about $11.1B in equity value and roughly $15.8B including debt, gaining the Xifaxan franchise.

18. 2015Bausch Health

    Drug pricing and Philidor scandal breaks

    Congressional investigators pressed Valeant over 525% and 212% increases on the heart drugs Isuprel and Nitropress, bought in February 2015, and over its undisclosed ties to the Philidor mail-order pharmacy.

19. 2016Bausch Health

    Joseph Papa replaces Pearson as chief executive

    Valeant named Perrigo chief executive Joseph C. Papa as chairman and CEO on April 25, 2016, and he took over in early May 2016 with about $30B of debt outstanding.

20. 2017Bausch Health

    Skincare brands and Dendreon sold to cut debt

    Valeant sold the CeraVe, AcneFree and AMBI skincare brands to L'Oreal for about $1.3B and the Dendreon cancer unit to China's Sanpower Group for about $820M, using the proceeds to repay debt.

21. 2018Bausch Health

    Company renamed Bausch Health Companies Inc.

    The name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was completed on July 13, 2018, and the shares began trading as BHC on the NYSE and TSX on July 16, 2018.

22. 2020Bausch Health

    SEC settlement closes the Philidor accounting case

    On July 31, 2020 Bausch Health agreed to pay a $45M civil penalty to settle SEC charges of improper revenue recognition and misleading disclosures tied to Philidor. Former chief executive J. Michael Pearson and two other executives also settled.

23. 2022Bausch Health

    Bausch + Lomb listed on the NYSE and TSX

    Bausch + Lomb common stock began trading under the ticker BLCO on May 6, 2022, and a Bausch Health subsidiary sold 35,000,000 Bausch + Lomb shares in the offering. Bausch Health retained about 88% of the eye-health company and still consolidates it. Thomas J.

24. 2023JPMorgan Chase

    First Republic Acquired from FDIC

    JPMorgan Chase acquired the substantial majority of First Republic Bank's assets and assumed deposits and certain liabilities from the FDIC.

25. 2025Bausch Health

    DURECT acquired and record annual revenue reported

    Bausch Health closed the DURECT acquisition on September 11, 2025 for about $63M upfront, completed Solta Medical's Chinese aesthetics distribution purchase on December 1, 2025, and reported FY2025 revenue of $10.266B, up 7%, with net income attributable to Ba…

26. 2025JPMorgan Chase

    FY2025 Net Revenue of $182.447B

    JPMorgan Chase reported U.S. GAAP total net revenue of $182.447 billion and net income of $57.048 billion. Its managed, fully taxable-equivalent segment presentation reported $185.581 billion of total net revenue across CCB, CIB, AWM, and Corporate.

27. 2026Bausch Health

    RED-C trials miss endpoints and trigger a $1.4 billion charge

    In January 2026 the two Phase 3 RED-C trials of amorphous-rifaximin soluble solid dispersion for primary prevention of hepatic encephalopathy missed their primary endpoints.

28. 2026Bausch Health

    Second-quarter 2026 revenue of $2.85 billion and raised guidance

    Bausch Health reported second-quarter 2026 revenue of $2.85B, up 13%, net income attributable to Bausch Health of $258M and adjusted EBITDA of $1.075B, and raised its full-year 2026 revenue, adjusted EBITDA and cash flow guidance.

29. 2026JPMorgan Chase

    Chase to Become Apple Card Issuer

    On January 7, 2026 Apple and Chase announced that Chase will replace Goldman Sachs as Apple Card issuer over about 24 months.

30. 2026JPMorgan Chase

    Co-Presidents Named

    Doug Petno and Troy Rohrbaugh were named co-presidents in June 2026, and Marianne Lake announced her retirement.

Acquisitions

Questions about Bausch Health vs JPMorgan Chase